4.6 Article

EU Framework 6 Project: Predictive Toxicology (PredTox)-overview and outcome

Journal

TOXICOLOGY AND APPLIED PHARMACOLOGY
Volume 252, Issue 2, Pages 73-84

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.taap.2010.10.008

Keywords

Toxicogenomics; Proteomic; Metabolomics; Predictive toxicology; FP6; Consortium

Funding

  1. EU
  2. European Union [LSHB-CT-2005-518170]
  3. Bayer-Schering Pharma-former Bayer and Schering
  4. Bio-Rad-former Ciphergen
  5. Boehringer Ingelheim
  6. F. Hoffmann-La Roche
  7. Genedata
  8. Johnson Johnson
  9. Lilly
  10. Merck-Serono-former Merck Darmstadt and Serono
  11. Novartis
  12. Novo-Nordisk
  13. Nycomed GmbH-former Altana Pharma AG
  14. sanofi-aventis
  15. Schering-Plough-former Organon
  16. Servier
  17. University College Dublin
  18. University of Hacettepe
  19. University of Wuerzburg

Ask authors/readers for more resources

In this publication, we report the outcome of the integrated EU Framework 6 Project: Predictive Toxicology (PredTox), including methodological aspects and overall conclusions. Specific details including data analysis and interpretation are reported in separate articles in this issue. The project, partly funded by the EU, was carried out by a consortium of 15 pharmaceutical companies, 2 SMEs, and 3 universities. The effects of 16 test compounds were characterized using conventional toxicological parameters and omics technologies. The three major observed toxicities, liver hypertrophy, bile duct necrosis and/or cholestasis, and kidney proximal tubular damage were analyzed in detail. The combined approach of omics and conventional toxicology proved a useful tool for mechanistic investigations and the identification of putative biomarkers. In our hands and in combination with histopathological assessment, target organ transcriptomics was the most prolific approach for the generation of mechanistic hypotheses. Proteomics approaches were relatively time-consuming and required careful standardization. NMR-based metabolomics detected metabolite changes accompanying histopathological findings, providing limited additional mechanistic information. Conversely, targeted metabolite profiling with LC/GC-MS was very useful for the investigation of bile duct necrosis/cholestasis. In general, both proteomics and metabolomics were supportive of other findings. Thus, the outcome of this program indicates that omics technologies can help toxicologists to make better informed decisions during exploratory toxicological studies. The data support that hypothesis on mode of action and discovery of putative biomarkers are tangible outcomes of integrated omics analysis. Qualification of biomarkers remains challenging, in particular in terms of identification, mechanistic anchoring, appropriate specificity, and sensitivity. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available